GOSS — Gossamer Bio, Inc.

Free edition. This report shows the public record for GOSS. The full signal timeline, group mix, and marked chart are member content — see the box at the end.

Mid cap · Healthcare — Drug Manufacturers - Specialty & Generic · Latest close $9.42 · Thu, Nov 5, 2026 · Market cap now $61M

CONFIRMED SIGNALS ON RECORD	MEDIAN RETURN SINCE EARLY SIGNAL (REFERENCE ONLY)	GAINED +10% WITHIN 90 DAYS (DECIDED SIGNALS)	BEAT THE S&P 500 SINCE CONFIRMATION
4	-94.7%	3 of 4	0 of 4

Headline statistics: confirmed signals only, measured from the confirmation price.

Since January 2022, Gossamer has had six Early signals, four confirmed. Three of the four decided signals gained +10% within 90 days, and zero of four finished ahead of the S&P 500 since confirmation. Three signals carried a caution flag. Two Early signals never confirmed and count in no statistic.

Weekly closes (adjusted). Signal marks are member content and are not drawn on the free-edition chart.



🔒 Members get the full GOSS record

- The full signal timeline — every Early signal with its exact dates, group tag, and caution flags
- The group mix — how this stock's confirmed signals split across the groups
- The price chart with every Early and Confirmed signal marked on it
- Entry prices and per-signal grading in the member screener

See membership options at **trifectasignals.com**

Trifecta Signals flags oversold stocks as they turn bullish — three oversold signals, one Early Signal — and tracks every signal in the open. Statistics are confirmed-only. This report is the public record for GOSS; it is not investment advice.